pharmaphorum1 天
Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drug
Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...
pharmaphorum4 天
Mylan launches Advair generic at 70% discount in US
Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...